ARC: a framework for access, reciprocity and conduct in psychedelic therapies
In a within‑subjects intravenous LSD versus placebo study using computational reinforcement‑learning modelling, LSD increased reward (and to a lesser extent punishment) learning rates and reduced stimulus stickiness, producing greater exploration while leaving simple win‑stay/lose‑shift measures unchanged. These effects indicate heightened plasticity that could facilitate the revision of maladaptive associations in clinical psychedelic therapy.
Authors
- Meg Spriggs
- Ashleigh Murphy-Beiner
- Robin Murphy
Published
Abstract
Background
The non-selective serotonin 2A (5-HT 2A ) receptor agonist lysergic acid diethylamide (LSD) holds promise as a treatment for some psychiatric disorders. Psychedelic drugs such as LSD have been suggested to have therapeutic actions through their effects on learning. The behavioural effects of LSD in humans, however, remain incompletely understood. Here we examined how LSD affects probabilistic reversal learning (PRL) in healthy humans.
Methods
Healthy volunteers received intravenous LSD (75 μ g in 10 mL saline) or placebo (10 mL saline) in a within-subjects design and completed a PRL task. Participants had to learn through trial and error which of three stimuli was rewarded most of the time, and these contingencies switched in a reversal phase. Computational models of reinforcement learning (RL) were fitted to the behavioural data to assess how LSD affected the updating (‘learning rates’) and deployment of value representations (‘reinforcement sensitivity’) during choice, as well as ‘stimulus stickiness’ (choice repetition irrespective of reinforcement history).
Results
Raw data measures assessing sensitivity to immediate feedback (‘win-stay’ and ‘lose-shift’ probabilities) were unaffected, whereas LSD increased the impact of the strength of initial learning on perseveration. Computational modelling revealed that the most pronounced effect of LSD was the enhancement of the reward learning rate. The punishment learning rate was also elevated. Stimulus stickiness was decreased by LSD, reflecting heightened exploration. Reinforcement sensitivity differed by phase.
Conclusions
Increased RL rates suggest LSD induced a state of heightened plasticity. These results indicate a potential mechanism through which revision of maladaptive associations could occur in the clinical application of LSD.
Research Summary of 'ARC: a framework for access, reciprocity and conduct in psychedelic therapies'
Introduction
Research into LSD as a potential psychiatric treatment has re-emerged, with theorised benefits centred on effects on learning and neural plasticity. The serotonin 2A (5-HT2A) receptor is considered a key target mediating psychedelic effects and plasticity, and animal studies have shown that 5-HT2A agonists and LSD can influence associative learning. Serotonin and dopamine systems are both implicated in adaptive behavioural flexibility and reversal learning, and prior human studies of LSD and other psychedelics have examined a range of cognitive and affective domains but have not comprehensively addressed the mechanisms of instrumental learning and probabilistic choice under uncertainty in humans. The authors set out to test how LSD alters instrumental conditioning and cognitive flexibility using a probabilistic reversal learning (PRL) paradigm in healthy volunteers. They aimed both to assess overt behavioural changes using standard measures (for example win-stay/lose-stay and perseveration) and to probe underlying learning mechanisms by fitting computational reinforcement-learning (RL) models. Specific questions included whether LSD modulates sensitivity to immediate feedback, changes the rate at which choice values are updated (learning rates), and alters exploratory behaviour (indexed as reinforcement sensitivity and stimulus stickiness).
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- Compound
- Topic
- Authors
- APA Citation
Kanen, J. W., Luo, Q., Rostami Kandroodi, M., Cardinal, R. N., Robbins, T. W., Nutt, D. J., Carhart-Harris, R. L., & den Ouden, H. E. M. (2023). ARC: a framework for access, reciprocity and conduct in psychedelic therapies. Psychological Medicine, 53(14), 6434-6445. https://doi.org/10.1017/S0033291722002963
References (29)
Papers cited by this study that are also in Blossom
Barrett, F. S., Carbonaro, T. M., Hurwitz, E. et al. · Psychopharmacology (2018)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Doss, M. K., Weafer, J. J., Gallo, D. A. et al. · Neuropsychopharmacology (2017)
Show all 29 referencesShow fewer
Schilbach, L., Stämpfli, P., Vollenweider, F. X. et al. · Scientific Reports (2020)
Family, N., Maillet, E. L., Williams, L. T. J. et al. · Psychopharmacology (2019)
Family, N., Vinson, D., Vigliocco, G. et al. · Language Cognition and Neuroscience (2016)
Goldberg, S. B., Pace, B. T., Nicholas, C. R. et al. · Psychiatry Research (2020)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · European Neuropsychopharmacology (2020)
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · ACS Pharmacology and Translational Science (2020)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)
Lafrance, A., Loizaga-Velder, A., Fletcher, J. et al. · Journal of Psychoactive Drugs (2017)
Mason, N. L., Mischler, E., Uthaug, M. V. et al. · Journal of Psychoactive Drugs (2019)
Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)
Nichols, D. E. · Pharmacology and Therapeutics (2004)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Schmidt, A., Müller, F., Lenz, C. et al. · Psychological Medicine (2017)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Yanakieva, S., Polychroni, N., Family, N. et al. · Psychopharmacology (2018)
Cited By (3)
Papers in Blossom that reference this study
Ertl, N., Ashraf, I., Azizi, L. et al. · Biorxiv (2025)
Casanova, A. F., Ort, A., Smallridge, J. W. et al. · iScience (2024)
Buchborn, T., Kettner, H., Kartner, L. et al. · Frontiers in Neuroscience (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.